- Proprietary lipophilic enhancement technology boosts bioavailability of orally ingested cannabinoids and masks unpleasant taste
- Only company in the world to obtain a patent for improved oral or ingestible delivery of all cannabinoids, including both non-psychoactive and psychoactive
- Company generates revenue from out-licensing its technology
The cannabis market is exploding globally as well as domestically, and Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has pioneered an enabling technology that enhances the body’s absorption of cannabinoids—an advancement from which many cannabis-related companies can profit.
Lexaria’s proprietary lipophilic enhancement technology has demonstrated the ability to boost the bioavailability of all orally ingested cannabinoids. The body’s gastrointestinal tract poorly absorbs cannabinoids—whether ingested in pill form or via cannabis edibles—so smoking as a means of cannabis administration has been the norm for many users in order to achieve greater effectiveness. Lexaria’s technology, however, enables the body to derive greater effect from orally administered cannabinoids without the vehicle of smoking. The company’s patented process increases bio-absorption of cannabinoids by between five- and ten-fold and, additionally, reduces onset time by about 75 percent.
Read the full article